SCHEMBL9987274

SCHEMBL9987274

CC(O)c1cc2ccc(Cl)cc2n1-c1cccc(F)c1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.41
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
KCNH2 Q12809 3/20 0.41
MAT2A P31153 2/20 0.40
PLA2G10 O15496 2/20 0.40
PLA2G2A P14555 1/20 0.40
TDP2 O95551 2/20 0.38
GCGR P47871 1/20 0.36
PIK3CD O00329 1/20 0.35
AHR P35869 1/20 0.35
MAPK8 P45983 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9986522 0.87 MAT2A (0.40) NOTUMSLC6A2SLC6A4KCNH2MAT2A
SCHEMBL9987033 0.84 NOTUM (0.42) NOTUMSLC6A2SLC6A4PLA2G10
SCHEMBL9986976 0.80 MAT2A (0.38) NOTUMSLC6A2SLC6A4MAT2APLA2G10
SCHEMBL9986472 0.76 MAT2A (0.42) NOTUMSLC6A2SLC6A4MAT2APLA2G10
SCHEMBL9987051 0.74 MAT2A (0.42) NOTUMMAT2APLA2G10PLA2G2ATDP2
SCHEMBL9987544 0.72 PIK3CD (0.45) PIK3CD
SCHEMBL9987241 0.72 PLA2G10 (0.47) NOTUMMAT2APLA2G10PLA2G2AGCGR
SCHEMBL9986428 0.70 PLA2G10 (0.40) NOTUMPLA2G10PIK3CD
SCHEMBL17718408 0.70 ALDH1A1 (0.53) PLA2G10
SCHEMBL9986971 0.68 NOTUM (0.45) NOTUMPLA2G10PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062055-B2 Fused pyrrole derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2015-06-23 US disclosed
US-9062055-B2 Fused pyrrole derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2015-06-23 US disclosed
US-9062055-B2 Fused pyrrole derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2015-06-23 US disclosed
WO-2011163195-A1 FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-12-29 WO disclosed
WO-2011163195-A1 FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-12-29 WO disclosed
US-20110312979-A1 FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-12-22 US disclosed
US-20110312979-A1 FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-12-22 US disclosed
US-20110312979-A1 FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312979-A1 FUSED PYRROLE DERIVATIVES AS PI3K INHIBITORS PIK3R5, PIK3R4, PIK3CA NOTUM 3369/4885SLC6A2 4875/4885SLC6A4 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.